Literature DB >> 18436392

Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.

David Groheux1, Jean-Luc Moretti, Georges Baillet, Marc Espie, Sylvie Giacchetti, Elif Hindie, Christophe Hennequin, Jacques-Robert Vilcoq, Caroline Cuvier, Marie-Elisabeth Toubert, Jean-Emmanuel Filmont, Farid Sarandi, Jean-Louis Misset.   

Abstract

PURPOSE: To investigate the potential effect of using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in the initial assessment of patients with clinical Stage II or III breast cancer. METHODS AND MATERIALS: During 14 consecutive months, 39 patients (40 tumors) who presented with Stage II or III breast cancer on the basis of a routine extension assessment were prospectively included in this study. PET/CT was performed in addition to the initial assessment.
RESULTS: In 3 cases, PET/CT showed extra-axillary lymph node involvement that had not been demonstrated with conventional techniques. Two of these patients had hypermetabolic lymph nodes in the subpectoral and infraclavicular regions, and the third had a hypermetabolic internal mammary node. PET/CT showed distant uptake in 4 women. Of these 4 women, 1 had pleural involvement and 3 had bone metastasis. Overall, of the 39 women, the PET/CT results modified the initial stage in 7 (18%). The modified staging altered the treatment plan for 5 patients (13%). It led to radiotherapy in 4 patients (bone metastasis, pleural lesion, subpectoral lymph nodes, and internal mammary nodes) and excision of, and radiotherapy to, the infraclavicular lymph nodes in 1 patient.
CONCLUSIONS: PET/CT can provide information on extra-axillary lymph node involvement and can uncover occult distant metastases in a significant percentage of patients. Therefore, initial PET/CT could enable better treatment planning for patients with Stage II and III breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18436392     DOI: 10.1016/j.ijrobp.2008.02.056

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  38 in total

1.  Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer.

Authors:  Naoki Niikura; Jun Liu; Colleen M Costelloe; Shana L Palla; John E Madewell; Naoki Hayashi; Tse-Kuan Yu; Yutaka Tokuda; Richard L Theriault; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Present and future role of FDG-PET/CT imaging in the management of breast cancer.

Authors:  Kazuhiro Kitajima; Yasuo Miyoshi
Journal:  Jpn J Radiol       Date:  2016-01-05       Impact factor: 2.374

Review 3.  Should FDG PET/CT be used for the initial staging of breast cancer?

Authors:  David Groheux; Elif Hindié; Domenico Rubello; Marc Espié; Georges Baillet; Sylvie Giacchetti; Jean-Louis Misset; Jean-Luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10       Impact factor: 9.236

4.  ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.

Authors:  Alexandre Cochet; Inna Dygai-Cochet; Jean-Marc Riedinger; Olivier Humbert; Alina Berriolo-Riedinger; Michel Toubeau; Séverine Guiu; Charles Coutant; Bruno Coudert; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-07       Impact factor: 9.236

5.  Use of imaging for staging of early-stage breast cancer in two integrated health care systems: adherence with a choosing wisely recommendation.

Authors:  Erin E Hahn; Tania Tang; Janet S Lee; Corrine Munoz-Plaza; Joyce O Adesina; Ernest Shen; Braden Rowley; Jared L Maeda; David M Mosen; John C Ruckdeschel; Michael K Gould
Journal:  J Oncol Pract       Date:  2015-04-21       Impact factor: 3.840

6.  (18) F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities?

Authors:  J Krammer; A Schnitzer; C G Kaiser; K A Buesing; E Sperk; J Brade; S Wasgindt; M Suetterlin; S O Schoenberg; E J Sutton; K Wasser
Journal:  Eur Radiol       Date:  2015-02-15       Impact factor: 5.315

Review 7.  Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment.

Authors:  David Krug; René Baumann; Wilfried Budach; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; Marc D Piroth; Felix Sedlmayer; Rainer Souchon; Frederik Wenz; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2018-07-04       Impact factor: 3.621

8.  Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging.

Authors:  Diomidis Botsikas; Anastasia Kalovidouri; Minerva Becker; Michele Copercini; Dahila Amal Djema; Alexandre Bodmer; Sindy Monnier; Christoph D Becker; Xavier Montet; Benedicte M A Delattre; Osman Ratib; Valentina Garibotto; Claire Tabouret-Viaud
Journal:  Eur Radiol       Date:  2015-10-17       Impact factor: 5.315

9.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

10.  The Role of F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast Cancer.

Authors:  Naoki Niikura; Naoto T Ueno
Journal:  J Cancer       Date:  2010-06-22       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.